On Friday, Abionyx Pharma unveiled encouraging preclinical results in brain fog, which it believes will support the clinical development of its CER-001 in new indications.

The biotech group states that these data show that administration of CER-001 attenuated systemic inflammation and regulated indolamine-2,3-dioxygenase (IDO1), thereby reducing neuroactive metabolites and retention of residual substances.

Overall, this work indicates that treatment with CER-001 may improve renal and cognitive function in sepsis-induced acute renal failure," he adds.

From Abionyx's perspective, these preclinical data support the hypothesis that the use of CER-001 may have the potential to improve renal and cognitive function.

These findings were presented at the first international scientific congress dedicated to brain-kidney interaction, currently taking place in Naples.

Listed on the Paris Bourse, Abionyx Pharma shares climbed over 5% on Friday following these announcements.

Copyright (c) 2023 CercleFinance.com. All rights reserved.